40例腹膜后纤维化临床资料回顾

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (735 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To provide more evidence－based medical evidence for the diagnosis and treatment of retroperitoneal fibrosis.Methods The clinical data about forty patients with retroperitoneal fibrosis diagnosed and treated in two clinical centers between 2008 and 2019 was retrospectively analyzed. Such information as demographic characteristics, clinical manifestations, laboratory findings, radiological findings, modalities of treatments with RPF, outcomes of treatment and prognosis of some patients was retrieved from the electronic medical record information systems of the two hospitals. Scheel’s method was used for radiographic classification.Results These patients ranged from 24 to 83 in age, with an average age of 59.13±14.7. Thirty-one of them were males, and the ratio of males to females was 3.5∶1;Twenty-nine of the male patients smoked to different extents but none of the female patients was a smoker. 65% of the patients had such initial symptoms as abdominal pain or back pain or both, followed by leg edema. 5% of the patients without symptoms were spotted by medical examination. Some of the patients had elevated inflammation indexes. In terms of radiographic classification, most of the patients were of Class Ⅰ+Ⅲ, followed by Class I. IgG4 was tested in ten patients and was found to increase in five of these patients, and it was ten times higher than the normal value in one of the patients. The four male patients with higher IgG4 were heavy smokers.Conclusions The cross-sectional studies in the two centers show that most of the patients with retroperitoneal fibrosis are males and advanced in age. CT and MRI scans are the most common and useful tools in the diagnosis of RPF. PET-CT scans are very helpful in diagnosis of retroperitoneal fibrosis. Pathological diagnosis can help clarify the cause of the disease. Management of RPF includes medical therapy and ureteral stenting in the event of severe hydronephrosis. Glucocorticoids are the mainstay RPF treatment.

Key words： retroperitoneal fibrosis medication combination clinical center

Received: 17 February 2020

ZTFLH:

R572

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Aiwu
	ZHANG Chunyan
	ZHAO Miansong

Cite this article:

LIU Aiwu,ZHANG Chunyan,ZHAO Miansong. Retroperitoneal fibrosis: a retrospective analysis of clinical data on 40 patients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(8): 703-706.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I8/703

[1]	Khosroshahi A, Carruthers M N, Stone J H, et al. Rethinking Ormond’s disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease[J]. Medicine,2013,92(2): 82-91.
[2]	管星庆, 阚云珍, 柳菊, 等. 特发性腹膜后纤维化IgG4的表达及观察[J]. 医药论坛杂志,2015,36(3):57-61.
[3]	吴哲, 孙露露, 李宁, 等. IgG4相关性腹膜后纤维化CT表现及实验室检查综合诊断价值分析[J]. 航空航天医学杂志,2016,27(12): 1504-1508.
[4]	Van Bommel E F, Jansen I, Hendriksz T R, et al. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation[J]. Medicine,2009,88(4): 193-201.
[5]	王学梅, 郑秀环. 儿童腹膜后纤维化1例报告[J]. 临床儿科杂志,2005,8(6): 363-397.
[6]	Subramani A V, Lockwood G M, Jetton J G, et al. Pediatric idiopathic retroperitoneal fibrosis[J]. Radiol Case Rep,2019,14(4): 459-462.
[7]	Fujimori N, Ito T, Igarashi H, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease [J]. World J Gastroenterol,2013,19(1): 35-41.
[8]	Liao S, Wang Y, Li K, et al. Idiopathic retroperitoneal fibrosis: a cross-sectional study of 142 Chinese patients[J]. Scand J Rheumatol,2018,47(3): 198-205.
[9]	杜开放, 吕文才, 王希春, 等. 以急性阑尾炎为表现的腹膜后纤维化1例[J]. 中国现代普通外科进展,2018,21(7): 519.
[10]	徐文文, 崔建国, 张清潭. 以下肢静脉血栓形成为首发表现的腹膜后纤维化一例报道并文献复习[J]. 中国全科医学,2014,17(25): 3028-3030.
[11]	Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis[J]. Kidney Int,2007,72(6): 742-53.
[12]	邸丽娟, 张建华, 范岩,等. (18)F-FDGPET/CT诊断腹膜后纤维化[J]. 中国介入影像与治疗学,2018,15(2): 90-94.
[13]	黄杰, 王绍武, 李相文,等. 多层螺旋CT评价特发性腹膜后纤维化炎性反应活动性可行性的初步研究[J]. 浙江医学,2020,42(3): 236-239.
[14]	Fukukura Y, Fujiyoshi F, Nakamura F, et al. Autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis[J]. AJR Am J Roentgenol,2003,181(4): 993-995.
[15]	王大伟, 贺祎, 张文君. 腹膜后纤维化的超声特征分析[J]. 临床超声医学杂志,2018,20(10): 709-711.
[16]	刘艳莎, 赵晓宁, 王萤萤,等. 特发性腹膜后纤维化的超声诊断价值[J]. 中国超声医学杂志,2018,34(12): 1105-1107.
[17]	陈胜江, 尚智伟, 刘一靖,等. 超声引导穿刺活检诊断腹膜后纤维化[J]. 中国临床医学影像杂志,2018,29(1): 38-41.
[18]	Pelkmans L G, Hendriksz T R, Westenend P J, et al. Elevated serum IgG4 levels in diagnosis and treatment response in patients with idiopathic retroperitoneal fibrosis[J]. Clin Rheumatol,2017,36(4): 903-912.
[19]	Caiafa R O, Vinuesa A S, Izquierdo R S, et al. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up[J]. Radiographics,2013,33(2): 535-52.
[20]	Kermani T A, Crowson C S, Achenbach S J, et al. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes[J]. Mayo Clin Proc,2011,86(4): 297-303.
[21]	高琛妮, 沈平雁, 潘召城,等. 腹膜后纤维化7例的临床特点和治疗方案分析[J]. 上海医学,2017,40(1): 41-44.
[22]	Scheel P J, Sozio S M, Feeley N. Medical management of retroperitoneal fibrosis[J]. Trans Am Clin Climatol Assoc,2012,123: 283-290.
[23]	尹清, 刘必成. 以急性肾衰竭为主要表现的腹膜后纤维化1例并文献复习[J]. 临床荟萃,2017,32(8): 717-721.
[24]	张伟, 薛峰, 王淑娟,等. IgG4相关腹膜后纤维化致肾衰竭10例临床分析[J]. 青岛大学学报(医学版),2020,56(1): 92-94.
[25]	Moriconi D, Giannese D, Capecchi R, et al. Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis[J]. Clin Exp Nephrol,2019,23(9): 1147-1153.